Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (89)	2/26/1999 4:02:00 PM
From: tuck	Read Replies (2) \| Respond to of 423

Braveheart, What do you think of IMGN? I liked their technology, but they were near bankruptcy for a couple of years. Now they have a partner ready to fund trials (I believe it was SmithKline). The murine data for their cancer drug is excellent. Wiped out lung cancer in combo with small doses of existing chemotherapeutics. No mention of side-effects. Those willing to gamble that it will translate into good human data might look to get in now. Toxicity/dosage trials begin this year. It's been sitting in the twos for the three years that I've checked on it. It may be ready to break a little higher now. Also curious on the thread's take on CORR. P.S. Those who act on my recommendations with a good two week lag will do better than if they had not :~) Cheers, Tuck